DG Comp issues fresh pay-for-delay charge
The EU’s competition watchdog has accused drugmaker Teva and subsidiary Cephalon – a former rival – of signing an illegal patent settlement in which Teva agreed to delay the entry of a generic sleep disorder drug.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.